Structure of SALO, a leishmaniasis vaccine candidate from the sand fly Lutzomyia longipalpis.

• Published in: PLOS Neglected Tropical Diseases
• Main Authors: Oluwatoyin A Asojo, Alan Kelleher, Zhuyun Liu, Jeroen Pollet, Elissa M Hudspeth, Wanderson C Rezende, Mallory Jo Groen, Christopher A Seid, Maha Abdeladhim, Shannon Townsend, Waldione de Castro, Antonio Mendes-Sousa, Daniella Castanheira Bartholomeu, Ricardo Toshio Fujiwara, Maria Elena Bottazzi, Peter J Hotez, Bin Zhan, Fabiano Oliveira, Shaden Kamhawi, Jesus G Valenzuela
• Format: Article in Journal/Newspaper
• Language: English
• Published: Public Library of Science (PLoS) 2017
• Subjects: Arctic medicine. Tropical medicine; RC955-962; Public aspects of medicine; RA1-1270; Arctic; Salo
• Online Access: https://doi.org/10.1371/journal.pntd.0005374; https://doaj.org/article/79f22f7975c54654901cb554512a5886

BACKGROUND:Immunity to the sand fly salivary protein SALO (Salivary Anticomplement of Lutzomyia longipalpis) protected hamsters against Leishmania infantum and L. braziliensis infection and, more recently, a vaccine combination of a genetically modified Leishmania with SALO conferred strong protection against L. donovani infection. Because of the importance of SALO as a potential component of a leishmaniasis vaccine, a plan to produce this recombinant protein for future scale manufacturing as well as knowledge of its structural characteristics are needed to move SALO forward for the clinical path. METHODOLOGY/PRINCIPAL FINDINGS:Recombinant SALO was expressed as a soluble secreted protein using Pichia pastoris, rSALO(P), with yields of 1g/L and >99% purity as assessed by SEC-MALS and SDS-PAGE. Unlike its native counterpart, rSALO(P) does not inhibit the classical pathway of complement; however, antibodies to rSALO(P) inhibit the anti-complement activity of sand fly salivary gland homogenate. Immunization with rSALO(P) produces a delayed type hypersensitivity response in C57BL/6 mice, suggesting rSALO(P) lacked anti-complement activity but retained its immunogenicity. The structure of rSALO(P) was solved by S-SAD at Cu-Kalpha to 1.94 Å and refined to Rfactor 17%. SALO is ~80% helical, has no appreciable structural similarities to any human protein, and has limited structural similarity in the C-terminus to members of insect odorant binding proteins. SALO has three predicted human CD4+ T cell epitopes on surface exposed helices. CONCLUSIONS/SIGNIFICANCE:The results indicate that SALO as expressed and purified from P. pastoris is suitable for further scale-up, manufacturing, and testing. SALO has a novel structure, is not similar to any human proteins, is immunogenic in rodents, and does not have the anti-complement activity observed in the native salivary protein which are all important attributes to move this vaccine candidate forward to the clinical path.